Skip to content

Trial Summary

A phase II randomised controlled trial to determine the efficacy of combining the HDAC inhibitor sodium valproate with EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment of patients with RAS wild type metastatic colorectal cancer (VADER study).



ACTRN/NCT /ethics:

Scientific title:

Sponsor / Cooperative group:

GI Cancer

Trial & Patient Characteristics

Cancer TypeColorectal
Trial TypeInterventional
PhasePhase II
Age Range18 Years and older  
Tumour Stream -
Cancer Stage-
Anticipated Start Date2022-01-23
Anticipated End Date2024-06-01

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlison Richards
Phone08 8206 4835
Principal InvestigatorChris Karapetis
Recruitment StatusRecruiting